Gelsolin regulates proliferation, apoptosis, migration and invasion in human oral carcinoma cells

Oncology Letters

Volumn 9, Issue 5, 2015, Pages 2129-2134

  Deng, Runzhi ^a   Hao, Jing ^b   Han, Wei ^a,b   Ni, Yanhong ^a,b   Huang, Xiaofeng ^a   Hu, Qingang ^a  

^a NANJING UNIVERSITY   (China)

^b Jiangsu Province Engineering Research Center of Stomatological Translational Medicine   (China)

Author keywords

Apoptosis; Cell motility; Cell proliferation; Gelsolin; Oral cancer; Squamous cell carcinoma

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; 7 AMINODACTINOMYCIN; BETA ACTIN; FLUORESCEIN ISOTHIOCYANATE; GELSOLIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOCORTIN 5; PLASMID DNA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ASSAY; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA CELL LINE; UPREGULATION; WESTERN BLOTTING;

EID: 84925435081     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3002     Document Type: Article

References (40)

1. Uribe R and Jay D: A review of actin binding proteins: new perspectives. Mol Biol Rep 36: 121-125, 2009.
2. dos Remedios CG, Chhabra D, Kekic M, et al: Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 83: 433-473, 2003.
3. Winder SJ and Ayscough KR: Actin‑binding proteins. J Cell Sci 118: 651-654, 2005.
4. Dominguez R: Actin‑binding proteins ‑ a unifying hypothesis. Trends Biochem Sci 29: 572-578, 2004.
5. Janmey PA and Chaponnier C: Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol 7: 111-117, 1995.
6. Pollard TD and Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell 112: 453-465, 2003.
7. Li GH, Arora PD, Chen Y, McCulloch CA and Liu P: Multifunctional roles of gelsolin in health and diseases. Med Res Rev 32: 999-1025, 2012.
8. Shieh DB, Chen IW, Wei TY, et al: Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 42: 599-606, 2006.
9. Müllauer L, Fujita H, Ishizaki A and Kuzumaki N: Tumor‑suppressive function of mutated gelsolin in ras‑transformed cells. Oncogene 8: 2531-2536, 1993.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
11. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
12. Nomura H, Uzawa K, Ishigami T, et al: Clinical significance of gelsolin‑like actin‑capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer 8: 39, 2008.
13. Petersen PE: Oral cancer prevention and control ‑ the approach of the World Health Organization. Oral Oncol 45: 454-460, 2009.
14. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G and Gorgoulis VG: Advances in the biology of oral cancer. Oral Oncol 43: 523-534, 2007.
15. da Silva SD, Ferlito A, Takes RP, et al: Advances and applications of oral cancer basic research. Oral Oncol 47: 783-791, 2011.
16. Sciubba JJ: Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol 2: 239-251, 2001.
17. Ayscough KR: In vivo functions of actin‑binding proteins. Curr Opin Cell Biol 10: 102-111, 1998.
18. Tanaka M, Müllauer L, Ogiso Y, et al: Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 55: 3228-3232, 1995.
19. Noske A, Denkert C, Schober H, et al: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 41: 461-469, 2005.
20. Dosaka-Akita H, Hommura F, Fujita H, et al: Frequent loss of gelsolin expression in non‑small cell lung cancers of heavy smokers. Cancer Res 58: 322-327, 1998.
21. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A and Asch BB: Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 65: 11-21, 2001.
22. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH and Kim DY: Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 19: 218-224, 2004.
23. Ni XG, Zhou L, Wang GQ, et al: The ubiquitin‑proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med 14: 582-589, 2008.
24. Shieh DB, Godleski J, Herndon JE II, et al: Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer 85: 47-57, 1999.
25. Liao CJ, Wu TI, Huang YH, et al: Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance. Gynecol Oncol 120: 135-144, 2011.
26. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL and Hayoz D: Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 61: 2614-2623, 2004.
27. An JH, Kim JW, Jang SM, Kim CH, Kang EJ and Choi KH: Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 412: 44-49, 2011.
28. Koya RC, Fujita H, Shimizu S, et al: Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem 275: 15343-15349, 2000.
29. Kusano H, Shimizu S, Koya RC, et al: Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 19: 4807-4814, 2000.
30. Kwiatkowski DJ: Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 11: 103-108, 1999.
31. Sakurai N and Utsumi T: Posttranslational N‑myristoylation is required for the anti‑apoptotic activity of human tGelsolin, the C‑terminal caspase cleavage product of human gelsolin. J Biol Chem 281: 14288-14295, 2006.
32. Azuma T, Koths K, Flanagan L and Kwiatkowski D: Gelsolin in complex with phosphatidylinositol 4,5‑bisphosphate inhibits caspase‑3 and ‑9 to retard apoptotic progression. J Biol Chem 275: 3761-3766, 2000.
33. Galluzzi L and Kroemer G: Mitochondrial apoptosis without VDAC. Nat Cell Biol 9: 487-489, 2007.
34. Baines CP, Kaiser RA, Sheiko T, Craigen WJ and Molkentin JD: Voltage‑dependent anion channels are dispensable for mitochondrial‑dependent cell death. Nat Cell Biol 9: 550-555, 2007.
35. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
36. Ke H, Parron VI, Reece J, Zhang JY, Akiyama SK and French JE: BCL2 inhibits cell adhesion, spreading, and motility by enhancing actin polymerization. Cell Res 20: 458-469, 2010.
37. De Corte V, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J and Gettemans J: Gelsolin‑induced epithelial cell invasion is dependent on Ras‑Rac signaling. EMBO J 21: 6781-6790, 2002.
38. Azuma T, Witke W, Stossel TP, Hartwig JH and Kwiatkowski DJ: Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 17: 1362-1370, 1998.
39. Radwanska A, Litwin M, Nowak D, et al: Overexpression of lumican affects the migration of human colon cancer cells through up‑regulation of gelsolin and filamentous actin reorganization. Exp Cell Res 318: 2312-2323, 2012.
40. Litwin M, Nowak D, Mazur AJ, Baczynska D, Mannherz HG and Malicka‑Blaszkiewicz M: Gelsolin affects the migratory ability of human colon adenocarcinoma and melanoma cells. Life Sci 90: 851-861, 2012.